Stopping nucleot(s)ide analogues in non‐cirrhotic HBeAg‐negative chronic hepatitis B patients: HBsAg loss at 96weeks is associated with low baseline HBsAg levels

Background and AimsCurrent guidelines recommend long‐term nucleot(s)ide analogue (NA) therapy for patients with HBeAg‐negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss.MethodsWe performed a prospective multi‐centre coho...

Full description

Saved in:
Bibliographic Details
Published in:Alimentary pharmacology & therapeutics 2022-07, Vol.56 (2), p.310-320
Main Authors: Hall, Samuel A L, Burns, Gareth S, Anagnostou, Despina, Vogrin, Sara, Sundararajan, Vijaya, Ratnam, Dilip, Levy, Miriam T, Lubel, John S, Nicoll, Amanda J, Strasser, Simone I, Sievert, William, Desmond, Paul V, Ngu, Meng C, Angus, Peter, Sinclair, Marie, Meredith, Christopher, Matthews, Gail, Revill, Peter A, Jackson, Kathy, Littlejohn, Margaret, Bowden, D Scott, Locarnini, Stephen A, Kumar Visvanathan, Thompson, Alexander J
Format: Article
Language:English
Subjects:
Cirrhosis
Hepatitis
Hepatitis B
Hepatitis B e antigen
Hepatitis B surface antigen
Liver cirrhosis
Patients
Remission
Remission (Medicine)
Tenofovir
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Background and AimsCurrent guidelines recommend long‐term nucleot(s)ide analogue (NA) therapy for patients with HBeAg‐negative chronic hepatitis B (CHB). However, disease remission has been described after stopping NA therapy, as well as HBsAg loss.MethodsWe performed a prospective multi‐centre cohort study of stopping NA therapy. Inclusion criteria were HBeAg‐negative CHB, the absence of cirrhosis and HBVDNA
ISSN:0269-2813
1365-2036
DOI:10.1111/apt.16968